Catalog No.: PC-38723Not For Human Use, Lab Use Only.
CPI-613 (Devimistat) is an antimitochondrial metabolism agent that specifically induces inactivating phosphorylation of tumor cell PDH via stimulation of PDKs 1 to 4, inhibits KGDH function strongly and rapidly, selectively in tumor cells.
CPI-613 (Devimistat) is an antimitochondrial metabolism agent that specifically induces inactivating phosphorylation of tumor cell PDH via stimulation of PDKs 1 to 4, inhibits KGDH function strongly and rapidly, selectively in tumor cells.
CPI-613 down-regulated the expression of Cyclin D3, E1, E2, F, A2, B1 and CDK2 genes of BxPC-3 pancreatic cancer cells but not non-transformed NIH-3T3 mouse fibroblast cells.
CPI-613 induced a correspondingly rapid, powerful redox signal in tumor cell mitochondria.
CPI-613 demonstrated tumor growth inhibition in human xenograft mouse models.
Physicochemical Properties
M.Wt
388.584
Formula
C22H28O2S2
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
6,8-bis[(phenylmethyl)thio]-octanoic acid
References
1. Stuart SD, et al. Cancer Metab. 2014 Mar 10;2(1):4.
2. Pardee TS, et al. Clin Cancer Res. 2014 Oct 15;20(20):5255-64.
3. Lee KC, et al. Ann Transl Med. 2014 Sep;2(9):91.
